LifeClean International (LCLEAN) investor relations material

Executive summary

• Q3 revenue rose to 11,346 TSEK from 9,365 TSEK; adjusted EBITDA improved to -5,197 TSEK from -6,713 TSEK, while operating loss narrowed to -6,426 TSEK from -9,939 TSEK.

• Strategic priorities remain Healthcare, Agriculture and PFAS remediation, with commercial opportunities dependent on converting regulatory readiness and project work into recurring revenue.

Financial highlights

• Q3 revenue was 11,346 TSEK vs 9,365 TSEK; nine-month revenue was 39,661 TSEK vs 44,438 TSEK.

• Q3 adjusted EBITDA was -5,197 TSEK vs -6,713 TSEK; EBITDA was -5,503 TSEK vs -7,455 TSEK.

• Nine-month adjusted EBITDA was -14,869 TSEK vs -14,536 TSEK; EBITDA improved to -15,016 TSEK from -17,687 TSEK.

• Net loss was -6,546 TSEK in Q3 vs -10,227 TSEK; nine-month net loss was -18,870 TSEK vs -26,579 TSEK.

• Nine-month operating costs excluding depreciation fell to 55,104 TSEK from 62,736 TSEK, reflecting efficiency measures.

Outlook and guidance

• Commercial focus is on Healthcare, Agriculture and PFAS remediation; work with Arxada and discussions on partnerships and licensing outside Europe continue.

• UK REACH registration and UK biocide Article 95 listing establish a regulatory basis for developing sales in the UK; targeted approaches to private healthcare are being tested in selected markets.

• A first US PFAS-remediation project is planned through a partner; future volumes remain uncertain.

• Planned production coordination in Vadstena is intended to improve resource efficiency; financial discipline remains a priority while sales projects take time.